 Connection
Brandon Mcmahon to Treatment Outcome
This is a "connection" page, showing publications Brandon Mcmahon has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.147 |
|
|
|
-
Talpaz M, Gerds AT, Lyons R, Langmuir P, Hunter D, Lamothe B, Hou K, McMahon B. A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis. Leuk Res. 2025 Aug; 155:107732.
Score: 0.084
-
Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 12; 16(12):1500-1537.
Score: 0.013
-
Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Hendrie P, Lee AI, Lee JT, Mann J, McMahon B, Millenson MM, Morton C, Ortel TL, Ozair S, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Williams E, Zakarija A, Hammond L, Dwyer MA, Engh AM. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018 11; 16(11):1289-1303.
Score: 0.013
-
Wilberger AC, McMahon B, Ewalt MD. The power of the partner: defying expectations in a case of a myeloproliferative neoplasm with FGFR1 rearrangement. Leuk Lymphoma. 2019 04; 60(4):1095-1097.
Score: 0.013
-
Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Netw. 2017 10; 15(10):1193-1207.
Score: 0.012
-
Prince BT, McMahon BJ, Jain M, Peters AT. Meropenem tolerance in a patient with probable fulminant piperacillin-induced immune hemolytic anemia. J Allergy Clin Immunol Pract. 2015 May-Jun; 3(3):452-3.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|